I signed ASCO’s letter from America’s cancer doctors & providers urging policymakers to end the drug shortage crisis. Patients are still struggling to get the treatments they need. Add your voice to the push for solutions & sign the letter! #ASCOAdvocacy asco.quorum.us/campaign/56411…

Ran into ⁦⁦Sumanta K. Pal, MD, FASCO⁩ for a larger reunion! ⁦ASCO⁩ LDP was a great experience and great to catch up! ⁦Neelima Denduluri⁩ ⁦Suzanne Cole, MD⁩

Great to see ⁦Neelima Denduluri⁩ ⁦Suzanne Cole, MD⁩ at #GU24 ⁦ASCO⁩ LDP mini reunion!

An AM run was a great way to start the final day of #GU24 ASCO with Benjamin L Maughan Omar Alhalabi, MD Hyung Kim Michael Palliola Naomi Haas - looking forward to a run at the best conference! Maybe Sumanta K. Pal, MD, FASCO or Toni Choueiri, MD will join!

Bradley McGregor Pedro C Barata, MD MSc FACP Alliance for Clinical Trials in Oncology Dana-Farber Lank Center for Genitourinary Oncology A032201/STRIKE in development and will be an important addition to KN-564 esp for those with early progression (IMP) AVEO Oncology Alliance for Clinical Trials in Oncology NCI Center for Cancer Research #GU24

Excellent discussion by Pedro C Barata, MD MSc FACP placing KN564 data in context - a win for our patients! Looking forward to ongoing trials and building on success with STRIKE - pembro with or without tivozanib for high risk resected localized RCC Alliance for Clinical Trials in Oncology Dana-Farber Lank Center for Genitourinary Oncology Stephanie Berg

Pembrolizumab already shown to improve DFS improves overall survival in adjuvant setting for high risk localized disease and M1NED with 38% reduction in risk of death Toni Choueiri, MD Dana-Farber Lank Center for Genitourinary Oncology @DanaFarber

Had a great run yesterday so let’s do it again before we finish up an exciting #GU24 ASCO Meet in Marquis lobby at 6 am! Benjamin L Maughan Sumanta K. Pal, MD, FASCO Toni Choueiri, MD Omar Alhalabi, MD

Excited build upon the success of DAD now featured in Annals of Oncology and highlighted in excellent talk by Sumanta K. Pal, MD, FASCO DAD-IO opening soon with Dana-Farber Lank Center for Genitourinary Oncology Toni Choueiri, MD Guru P. Sonpavde, MD joaquim bellmunt @DanaFarber

In San Francisco for #GUCS24 - join Benjamin L Maughan and me in the Marquis lobby tomorrow at 6 am for a fun run before an exciting first day ASCO Sumanta K. Pal, MD, FASCO Toni Choueiri, MD

Excited to share results for the first trial to our knowledge combining ADCs in any malignancy - tolerable with encouraging efficacy

Let’s take advice from Phillip Pierorazio and focus on wellness with a refreshing outdoor run before the day begins! Meet in the lobby with Benjamin L Maughan at 645 tomorrow am. Sumanta K. Pal, MD, FASCO Michael Palliola Toni Choueiri, MD (virtually)

Zanzalitinib with activity in refractory RCC with manageable safety profile even in those patients who had previously received cabozantinib Sumanta K. Pal, MD, FASCO Toni Choueiri, MD Kidney Cancer

I am late to the twitter campaign but can't think of a more deserving or better person for ASCO board than Toni Choueiri, MD Vote to make him a member of the board old-prod.asco.org/about-asco/asc…

Now up in poster session ESMO - Eur. Oncology #2369P Nivo/Ipi active in bladder cancer with variant histologies - in cohort of 50 patients ORR is 37% - 50% in small cell! - representing unmet need for our patients Toni Choueiri, MD joaquim bellmunt Rana McKay Dana-Farber Lank Center for Genitourinary Oncology